Dashboard
1
With a growth in Net Profit of 13.6%, the company declared Outstanding results in Sep 25
- PRE-TAX PROFIT(Q) At CNY 26.78 MM has Grown at 2,337.66%
- NET PROFIT(Q) At CNY 27.21 MM has Grown at 719.47%
- INTEREST COVERAGE RATIO(Q) Highest at 3,802.33
2
With ROE of 3.15%, it has a fair valuation with a 2.47 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,603 Million (Small Cap)
78.00
NA
0.35%
-0.02
4.42%
2.55
Revenue and Profits:
Net Sales:
233 Million
(Quarterly Results - Dec 2025)
Net Profit:
16 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.21%
0%
-2.21%
6 Months
29.78%
0%
29.78%
1 Year
36.67%
0%
36.67%
2 Years
-4.21%
0%
-4.21%
3 Years
-50.54%
0%
-50.54%
4 Years
-32.5%
0%
-32.5%
5 Years
-0.98%
0%
-0.98%
Teyi Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.82%
EBIT Growth (5y)
-4.64%
EBIT to Interest (avg)
8.54
Debt to EBITDA (avg)
0.88
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.41
Tax Ratio
14.65%
Dividend Payout Ratio
121.95%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.69%
ROE (avg)
9.04%
Valuation key factors
Factor
Value
P/E Ratio
78
Industry P/E
Price to Book Value
2.47
EV to EBIT
68.52
EV to EBITDA
33.31
EV to Capital Employed
2.50
EV to Sales
5.08
PEG Ratio
NA
Dividend Yield
0.37%
ROCE (Latest)
3.64%
ROE (Latest)
3.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
232.70
232.20
0.22%
Operating Profit (PBDIT) excl Other Income
24.00
34.00
-29.41%
Interest
0.60
1.30
-53.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
16.50
14.50
13.79%
Operating Profit Margin (Excl OI)
28.80%
77.00%
-4.82%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 0.22% vs -27.87% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 13.79% vs -77.59% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
915.70
684.60
33.76%
Operating Profit (PBDIT) excl Other Income
147.30
91.20
61.51%
Interest
4.60
5.90
-22.03%
Exceptional Items
0.00
-11.60
100.00%
Consolidate Net Profit
81.70
20.50
298.54%
Operating Profit Margin (Excl OI)
85.20%
39.90%
4.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 33.76% vs -35.41% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 298.54% vs -91.90% in Dec 2024
About Teyi Pharmaceutical Group Co., Ltd. 
Teyi Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






